HARRY HUGHES, Governor

855

THE DEPARTMENT AND THE STATE BOARD OF PHARMACY SHALL
REGULATE THE MANUFACTURE, DISTRIBUTION, AND SALE OF
AMYGDALIN FOR USE IN THIS STATE, BUT ONLY TO ENSURE THAT THE
AMYGDALIN IS NOT ADULTERATED, CONTAMINATED BY
MICROORGANISMS, OR MISBRANDED.

REVISOR'S NOTE: This section is new language derived
without substantive change from former Article
43, § 133(d) and (e).

Defined terms: "Department" § 1-101
"Physician" § 1-101

18-303. DIETHYLSTILBESTROL.

(A)  PUBLIC INFORMATION CAMPAIGN.

(1)  THE SECRETARY SHALL ESTABLISH AND PROMOTE A
STATEWIDE PUBLIC INFORMATION CAMPAIGN ON DIETHYLSTILBESTROL
(DES).

(2)  THE PUBLIC INFORMATION CAMPAIGN SHALL:

(I)  TRY TO REACH EACH INDIVIDUAL WHO HAS
BEEN EXPOSED TO DIETHYLSTILBESTROL AND EACH OFFSPRING OF
THOSE INDIVIDUALS, TO ENCOURAGE THE INDIVIDUALS AND
OFFSPRING TO SEEK MEDICAL CARE FOR THE PREVENTION OR
TREATMENT OF CANCER THAT RESULTS FROM THE EXPOSURE TO
DIETHYLSTILBESTROL; AND

(II)  INCLUDE ANY OTHER MATTER THAT THE
SECRETARY CONSIDERS APPROPRIATE.

(B)  SCREENING PROGRAM.

THE SECRETARY SHALL EXPAND EXISTING CANCER SCREENING
PROGRAMS TO DETECT ANY CANCER OR OTHER ABNORMAL CONDITION
THAT RESULTS FROM EXPOSURE TO DIETHYLSTILBESTROL, INCLUDING
BREAST, CERVICAL, TESTICULAR, OR VAGINAL CANCER OR VAGINAL
ADENOSIS.

(C)  TRAINING PROGRAMS.

THE SECRETARY SHALL ESTABLISH A PROGRAM TO TRAIN
PHYSICIANS, PHYSICIAN PHYSICIAN'S ASSISTANTS, AND NURSES IN:

(1)  IDENTIFYING INDIVIDUALS WHO HAVE BEEN
EXPOSED TO DIETHYLSTILBESTROL;

(2)  DIAGNOSING AND TREATING ANY CANCER OR OTHER
ABNORMAL CONDITION THAT RESULTS FROM THE EXPOSURE; AND

(3)  PREVENTING EXPOSURE TO DIETHYLSTILBESTROL.